Family Medicine · Houston, TX
NPI
1265755813
Since 2010
Specialty
Family Medicine
Code 207Q00000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
9600 Bellaire Blvd, #201
Houston, TX, 77036
Phone (713) 778-0754
Groups this clinician bills Medicare through
Medicare paid, 2024
$93K
1,822 services
Medicare patients, 2024
128
Average age 78
Drug cost, 2024
$2.9M
10,991 prescriptions
Company payments, 2025
$3,701
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Zhengnan Yin was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 460 times for 113 patients. In total Zhengnan Yin billed 1,822 services in 45 codes, and Medicare paid $93K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-11-09.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 460 | 113 | $12.23 | $5,625 |
| 99214 Office E&M - Established | Office | 415 | 111 | $86.72 | $36K |
| 99213 Office E&M - Established | Office | 206 | 74 | $65.97 | $14K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 194 | 75 | $49.86 | $9,672 |
| G0506 Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) | Office | 70 | 69 | $35.06 | $2,454 |
| 99487 Chronic, Principal, and Transitional Care Management | Office | 65 | 64 | $97.60 | $6,344 |
| G0442 Annual alcohol misuse screening, 5 to 15 minutes | Office | 46 | 46 | $18.80 | $865 |
| G0444 Annual depression screening, 5 to 15 minutes | Office | 40 | 40 | $18.80 | $752 |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 40 | 40 | $130.02 | $5,201 |
| G0008 Administration of influenza virus vaccine | Office | 32 | 31 | $32.75 | $1,048 |
| 90658 Vaccine Product | Office | 24 | 23 | $21.42 | $514 |
| G0446 Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | Office | 24 | 24 | $25.06 | $601 |
| 99491 Chronic, Principal, and Transitional Care Management | Office | 24 | 23 | $67.97 | $1,631 |
| 99204 Office E&M - New | Office | 13 | 13 | $101.50 | $1,319 |
By year: 2022 $146K for 27,313 services; 2023 $84K for 1,292 services; 2024 $93K for 1,822 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| K1034 Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 384 | 46 | $11.81 | $4,534 |
| 81002 Clinical Chemistry | 24 | 14 | $3.44 | $82.56 |
Medicare prescription drug claims, 2024
In 2024, the drug Zhengnan Yin prescribed most often to Medicare patients was Atorvastatin Calcium, with 759 prescriptions and refills. In total Zhengnan Yin wrote 10,991 Medicare prescriptions that cost $2.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 759 | 2,233 | 236 | $3,670 |
| Vascepa Icosapent Ethyl | 757 | 1,895 | 197 | $668K |
| Rosuvastatin Calcium Generic | 464 | 1,363 | 163 | $3,375 |
| Losartan Potassium Generic | 367 | 1,068 | 122 | $1,893 |
| Amlodipine Besylate Generic | 365 | 1,046 | 124 | $1,602 |
| Tamsulosin Hcl Generic | 333 | 970 | 106 | $2,670 |
| Levothyroxine Sodium Generic | 248 | 721 | 71 | $2,135 |
| Finasteride Generic | 234 | 675 | 77 | $1,486 |
| Omeprazole Generic | 231 | 374 | 130 | $1,661 |
| Zolpidem Tartrate Generic | 219 | 230 | 56 | $1,628 |
| Losartan-Hydrochlorothiazide Losartan/Hydrochlorothiazide | 213 | 577 | 68 | $1,519 |
| Alendronate Sodium Generic | 208 | 585 | 65 | $1,032 |
| Atenolol Generic | 207 | 592 | 59 | $773 |
| Azithromycin Generic | 194 | 194 | 138 | $420 |
| Betamethasone Dipropionate Generic | 182 | 210 | 115 | $5,453 |
Brand drugs: 2,614 claims; generic drugs: 8,142 claims; opioid claims: 33.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Zhengnan Yin $3,701 ($3,701 in general payments such as food, travel and fees) from 20 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $881.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 27 | $881 |
| Gilead Sciences, Inc. GILD | 19 | $399 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 10 | $382 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 11 | $292 |
| Novo Nordisk Inc NVO | 11 | $253 |
| Pfizer Inc. PFE | 4 | $184 |
| Abbvie Inc. ABBV | 12 | $178 |
| Lilly USA, LLC LLY | 10 | $168 |
| Kowa Pharmaceuticals America, Inc. | 15 | $149 |
| GlaxoSmithKline, LLC. GSK | 6 | $149 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.